ADNEX risk model
Model unavailability - IOTA Message:
We are writing to you to explain why the web applications of ADNEX and of LR1, LR2 and SRRisk are no longer available on the IOTA website, and why the ADNEX app and the other IOTA apps are no longer available in app-store or Google play. The explanation is a change in the European Medical Device Regulation (MDR), a set of regulations that governs the sale and distribution of medical devices within the European Union (EU).
According to the new MDR, the ADNEX calculator and the other IOTA calculators (web-application, app for apple and android devices and any other applications of the IOTA calculators) are now classified as medical devices. As a result, these calculators must undergo a certification process before they can be legally made available to healthcare professionals. Therefore, we have suspended the availability of the ADNEX calculator and the other calculators on our website until we have received the required certification, and we have also removed them from app-store and google play.
The process of obtaining MDR certification for medical devices is complex, very expensive and time-consuming. The IOTA steering committee is now working hard to obtain certification of the ADNEX web application, but we cannot provide reliable information on how long this process may take.
Please, observe that it is not the ADNEX model itself that is questioned and needs "certification". The ADNEX model has been externally validated on thousands of patients in different countries and settings and has been shown to have excellent ability to discriminate between benign and maligant adenxal masses. It is the calculator itself (web-application or app for android and apple devises) that needs to obtain certification.
An ADNEX app and some of the other IOTA risk calculation apps are available in many ultrasound systems. The apps in ultrasound systems have the necessary certification according to the manufacturers of the ultrasound machines. If you do not have an ultrasound machine with the ADNEX app or any of the other IOTA apps, we suggest you use the IOTA Benign descriptors or the IOTA Simple Rules.
We are very sorry about the situation. We know it causes substantial inconvenience.
If you have any questions or concerns, please contact us. We will keep you informed about any updates regarding the availability of the IOTA calculators.
Thank you for your understanding and continued support.
The IOTA Steering Committee:
Ben van Calster
The ADNEX risk model can be used by medical doctors to diagnose ovarian cancer in women who have at least one persistent adnexal (ovarian, para-ovarian, and tubal) tumor and are considered to require surgery.1 ADNEX estimates the probability that an adnexal tumor is benign, borderline, stage I cancer, stage II-IV cancer, or secondary metastatic cancer (i.e. metastasis of non-adnexal cancer to the ovary). The model was developed by clinicians and statisticians from the International Ovarian Tumor Analysis (IOTA) group, and is based on clinical and ultrasound data from almost 6000 women recruited at 24 centers in 10 countries (Italy, Belgium, Sweden, Czech Republic, Poland, France, UK, China, Spain, and Canada).
The ADNEX model uses nine predictors. There are three clinical variables, age, serum CA-125 level, and type of center (oncology referral center vs other), and six ultrasound variables, maximal diameter of lesion, proportion of solid tissue, more than 10 cyst locules, number of papillary projections, acoustic shadows, and ascites. All patients included required surgery as judged by a local clinician. As with all current diagnostic models for adnexal tumors (e.g. IOTA models, RMI, ROMA) it implies that patients selected for expectant management were excluded when creating the model. As a consequence ADNEX cannot be applied to conservatively treated adnexal tumors.
The manuscript describing the model is published in the BMJ, and we append the abstract of the paper below.1 The ADNEX model has been externally validated in the original paper, and in six subsequent studies.2-7 These studies confirm the discrimination between benign and malignant masses. Further calibration results when presented are good. Discrimination between the five tumor types is more difficult to investigate due to the low prevalence of several categories, and the fact that this is a non-standard analysis that needs to be done with care.8 As a result, we wrote a letter to the editor about one of the validation studies.9 Nevertheless, available results are good.
ADNEX cannot replace training and experience in ultrasonography and cannot compensate for poor quality ultrasound equipment. The parameters used in ADNEX are based on the terms and definitions as published by the IOTA group.10
The ADNEX model is implemented electronically in various formats:
- App for Android – (Temporarily unavailable)
- App for iPhone – (Temporarily unavailable)
- Web application (Temporarily unavailable)
By installing this software you agree to the terms of the License Agreement as available in the disclaimer of the application.
- Van Calster B, et al. BMJ 2014;349:g5920.
- Epstein E, et al. Ultrasound Obstet Gynecol 2016;47:110-6.
- Araujo KG, et al.. Ultrasound Obstet Gynecol 2016 [Epub ahead of print].
- Szubert S, et al. Gynecol Oncol 2016;142:490-5.
- Sayasneh A, et al. Br J Cancer 2016;115:542-8.
- Meys EM, et al. Ultrasound Obstet Gynecol 2016 [Epub ahead of print].
- Joyeux E, et al. Gynecol Obstet Fertil 2016 [Epub ahead of print].
- Van Calster B, et al. Eur J Epidemiol 2012;27:761-70.
- Van Calster B, et al. Gynecol Oncol Reports 2016 [Epub ahead of print].
- Timmerman D, et al. Ultrasound Obstet Gynecol 2000;16:500-505.
To develop a risk prediction model to preoperatively discriminate between benign, borderline, stage I invasive, stage II-IV invasive, and secondary metastatic ovarian tumours.
Observational diagnostic study using prospectively collected clinical and ultrasound data.
24 ultrasound centres in 10 countries.
Women with an ovarian (including para-ovarian and tubal) mass and who underwent a standardised ultrasound examination before surgery. The model was developed on 3506 patients recruited between 1999 and 2007, temporally validated on 2403 patients recruited between 2009 and 2012, and then updated on all 5909 patients.
Main outcome measures
Histological classification and surgical staging of the mass.
The Assessment of Different NEoplasias in the adneXa (ADNEX) model contains three clinical and six ultrasound predictors: age, serum CA-125 level, type of centre (oncology centres v other hospitals), maximum diameter of lesion, proportion of solid tissue, more than 10 cyst locules, number of papillary projections, acoustic shadows, and ascites. The area under the receiver operating characteristic curve (AUC) for the classic discrimination between benign and malignant tumours was 0.94 (0.93 to 0.95) on temporal validation. The AUC was 0.85 for benign versus borderline, 0.92 for benign versus stage I cancer, 0.99 for benign versus stage II-IV cancer, and 0.95 for benign versus secondary metastatic. AUCs between malignant subtypes varied between 0.71 and 0.95, with an AUC of 0.75 for borderline versus stage I cancer and 0.82 for stage II-IV versus secondary metastatic. Calibration curves showed that the estimated risks were accurate.
The ADNEX model discriminates well between benign and malignant tumours and offers fair to excellent discrimination between four types of ovarian malignancy. The use of ADNEX has the potential to improve triage and management decisions and so reduce morbidity and mortality associated with adnexal pathology.